Granules India buys 12.5% stake in USpharma

The Hyderabad-based pharma firm Granules India Ltd, through its wholly owned subsidiary Granules Pharmaceuticals Inc (GPI), has entered into an agreement to acquire 12.5 percent stake in the US-based USpharma. This investment will enable Granules to participate in product selection and have right of first refusal to market the select products which are under development by USpharma.

USpharma is a development-stage pharmaceutical company specialising in research, development and manufacture of high entry-barrier generic pharmaceuticals, including controlled-release, controlled-substance and patent-challenge products. USpharma in collaboration with manufacturing partners had submitted five ANDAs with Paragraph IV certifications, out of which four ANDAs have already been out licensed to Granules exclusively.

ALSO READ: Granules India bags exclusive rights for USpharma Windlas' four products

USpharma has formulation development and manufacturing facilities in Philadelphia (USA), Mumbai and cGMP analytical laboratory in Kansas City (USA).

“The agreement with USpharma complements our internal product development program and expands our product portfolio by leveraging external product development capabilities. The successful development of limited competition products by USpharma provides further long-term growth for the company. We are impressed with USpharma's product development capabilities with niche pipeline and firmly believe that these products represent a substantial commercial opportunity,” said Krishna Prasad Chigurupati, chairman and managing director, Granules India Ltd.